ruzaltatug rezetecan

**Ruzaltatug rezetecan (SHR-A2009)** is an investigational antibody-drug conjugate (ADC) developed by Jiangsu Hengrui Pharmaceuticals and Suzhou Suncadia Biopharmaceuticals, featuring a humanized monoclonal antibody targeting **HER3 (ErbB3)** conjugated via a cleavable linker to **rezetecan**, a DNA topoisomerase I inhibitor payload derived from camptothecin. It is designed for the treatment of advanced solid tumors, particularly **non-small cell lung cancer (NSCLC)** with EGFR mutations post-TKI progression, where phase 1 data showed an objective response rate of 30% in NSCLC patients and a tolerable safety profile with primarily hematologic toxicities. Clinical trials are ongoing in NSCLC, breast cancer, esophageal squamous cell carcinoma, and other solid tumors, with encouraging antitumor activity reported across multiple studies.[1][2][6][8][11]

Brand names

SHR-A2009SHR-A-2009SHR-A 2009

Other names

SHR-A2009SHR-A-2009SHR-A 2009